Browsing by Author "Ndembi, N."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    P20-10. Differences in patterns of Gag-induced immunogenetic pressure occur between clades A and D chronic HIV-1 infection in a Ugandan population
    (Retrovirology, 2009) Serwanga, J.; Ndembi, N.; Nanteza, B.; Mugaba, S.; Pimego, E.; Pala, P.; Auma, B.; Lyagoba, F.; Kaleebu, P.
    We previously reported slow HIV-1 disease progression in this population to be associated with the inherent host HLA B allele-mediated ability to induce broader Gag T-cell responses and faster disease progression to be more associated with clade D than A. Since Gag escape mutations often reduce viral fitness leading to significant reduction in virus replication, in this study, we evaluated the immunogenetic characteristics of clades A and D-associated escape mutations that could be harnessed for vaccine design.
  • Thumbnail Image
    Item
    Transmitted Antiretroviral Drug Resistance Surveillance among Newly HIV Type 1-Diagnosed Women Attending an Antenatal Clinic in Entebbe, Uganda
    (AIDS research and human retroviruses, 2008) Ndembi, N.; Lyagoba, F.; Nanteza, B.; Kushemererwa, G.; Serwanga, J.; Mbidde, E. Katongole; Grosskurth, H.; Kaleebu, P.; on behalf of the Uganda HIV Drug Resistance Working Group
    To evaluate transmitted HIV-1 drug resistance and study the natural polymorphism in pol of HIV-1 strains of newly diagnosed women attending an antenatal clinic in Uganda we sequenced the protease and reverse transcriptase genes for 46 HIV-1 strains from the threshold surveillance. Of the 46 sequences analyzed, 48.0% were subtype A1 (n = 22), 39.0% subtype D (n = 18), 2.0% subtype A2 (n = 1), 2.0% subtype C (n = 1), and 9.0% intersubtype recombinant A1/D (n = 4). Overall, many minor mutations were identified in the protease sequences. None of the strains had major associated mutations to any RTI drug or drug class interest after genotyping 37 samples of our cohort. The HIV drug resistance prevalence estimate in Entebbe following the HIVDR-TS methodology is less than 5% as set out by WHO guidelines.